ReviewHeliyon2024
Barley a nutritional powerhouse for gut health and chronic disease defense.
Review in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Antihypertensive Effect of Perla and Esmeralda Barley (Metabolites · 2024Article
Corrections and comments
- Retraction · 2025-03-20Concerns/Issues about Referencing/Attributions · Investigation by Journal/Publisher · Objections by Author(s) · Unreliable Results and/or Conclusions ·
- Retracted
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Digestive issues are recognized as significant contributors to various chronic diseases, including obesity, diabetes, and cardiovascular disease. Barley, a traditional grain, offers considerable promise in addressing these health challenges due to unique nutritional and bioactive compounds. Objective: This review examines the therapeutic potential of various parts of barley, underutilized resource, for chronic disease prevention and management. Method: ology: A comprehensive literature search was conducted across multiple databases like Google Scholar, PubMed, and ISI Web of Science, to identify nutritional components and functional ingredients in barley that contribute to gut health and chronic disease mitigation. Results: The finding suggests that humans digest barley starch more slowly than wheat and rice, which benefits chronic disease management. Barley's high-molecular-weight β-glucan high content acts as a prebiotic, promotes gut health through microbiome modulation and short-chain fatty acid production, potentially preventing colon cancer and boosting immunity. Recent studies on exploring barley grass of high land showed functional ingredients such as flavonoids, saponarin lutonarin, superoxide dismutase, gamma-aminobutyric acid, polyphenols K, Ca, Se, tryptophan chlorophyll, and vitamins, suggesting potential for enhanced antioxidant activity and improved management of chronic conditions like diabetes, cholesterol, hypertension, cardiovascular health, liver protection, and even boosted immunity. Conclusion: This review underscores the therapeutic potential of barley and its components in chronic disease management, highlighting the need for well-designed clinical trials to translate these findings into effective interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.